Sulphonylureas and risk of cardiovascular disease: Systematic review and meta-analysis

Diabetic Medicine

Volumn 30, Issue 10, 2013, Pages 1160-1171

  Phung, O J ^a,b   Schwartzman, E ^a,b   Allen, R W ^a   Engel, S S ^c   Rajpathak, S N ^c  

^a WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

^b Western Diabetes Institute   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METFORMIN; SULFONYLUREA;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; DISEASE SEVERITY; HEART INFARCTION; HOSPITALIZATION; HUMAN; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW;

DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; HOSPITALIZATION; HUMANS; INCIDENCE; MALE; MYOCARDIAL INFARCTION; RISK FACTORS; STROKE; SULFONYLUREA COMPOUNDS;

EID: 84884711653     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.12232     Document Type: Review

References (51)

1. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364-1379.
2. ® (Glimepiride) Package Insert. Bridgewater, NJ: Sanofi-Aventis, 2009.
3. Inc Pfizer. Glucotrol® (Glipizide) Package Insert. New York: Pfizer Inc., 2006.
4. Inc Pfizer. Micronase® (Glyburide) Package Insert. New York: Pfizer Inc., 2009.
5. Gerstein HC, Ratner RE, Cannon CP, Serruys PW, Garcia-Garcia HM, van Es GA, et al. Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: the assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history trial. Circulation 2010; 121: 1176-1187.
6. Giles TD, Elkayam U, Bhattacharya M, Perez A, Miller AB. Comparison of pioglitazone vs glyburide in early heart failure: insights from a randomized controlled study of patients with type 2 diabetes and mild cardiac disease. Congest Heart Fail 2010; 16: 111-117.
7. Hermann LS, Schersten B, Melander A. Anti-hyperglycaemic efficacy, response prediction and dose-response relations of treatment with metformin and sulphonylurea, alone and in primary combination. Diabet Med 1994; 11: 953-960.
8. Mazzone T, Meyer PM, Feinstein SB, Davidson MH, Kondos GT, D'Agostino RB Sr, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. J Am Med Assoc 2006; 296: 2572-2581.
9. Rao AD, Kuhadiya N, Reynolds K, Fonseca VA. Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality?: A meta-analysis of observational studies. Diabetes Care 2008; 31: 1672-1678.
10. Bolen S, Wilson L, Vassy J, Feldman L, Yeh J, Marinopoulos S et al. Comparative effectiveness and safety of oral diabetes medications for adults with type 2 diabetes. Rockville (MD): Agency for Healthcare Research and Quality, July 2007. Available at http://www.ncbi.nlm.nih.gov/books/NBK43056/.
11. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. Br Med J 2011; 343: d5928.
12. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M et al. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Non-Randomized Studies in Meta-Analysis. Available at http://wwwohrica/programs/clinical_epidemiology/oxfordasp Last acces-sed 5 March 2013.
13. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.
14. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. Br Med J 2003; 327: 557-560.
15. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. Br Med J 1997; 315: 629-634.
16. Seck T, Nauck M, Sheng D, Sunga S, Davies MJ, Stein PP, et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: A 2-year study. Int J Clin Pract 2010; 64: 562-576.
17. Seino Y, Rasmussen MF, Nishida T, Kaku K. Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in japanese patients with type 2 diabetes. Curr Med Res Opin 2010; 26: 1013-1022.
18. Giles TD, Miller AB, Elkayam U, Bhattacharya M, Perez A. Pioglitazone and heart failure: results from a controlled study in patients with type 2 diabetes mellitus and systolic dysfunction. J Card Fail 2008; 14: 445-452.
19. Nissen SE, Nicholls SJ, Wolski K, Nesto R, Kupfer S, Perez A, et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: The Periscope randomized controlled trial. J Am Med Assoc 2008; 299: 1561-1573.
20. Jain R, Osei K, Kupfer S, Perez AT, Zhang J. Long-term safety of pioglitazone versus glyburide in patients with recently diagnosed type 2 diabetes mellitus. Pharmacotherapy 2006; 26: 1388-1395.
21. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-2443.
22. St John Sutton M, Rendell M, Dandona P, Dole JF, Murphy K, Patwardhan R et al. A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care 2002; 25: 2058-2064.
23. UKPDS Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
24. Andersson C, Olesen JB, Hansen PR, Weeke P, Norgaard ML, Jorgensen CH, et al. Metformin treatment is associated with a low risk of mortality in diabetic patients with heart failure: a retrospective nationwide cohort study. Diabetologia 2010; 53: 2546-2553.
25. Brownstein JS, Murphy SN, Goldfine AB, Grant RW, Sordo M, Gainer V, et al. Rapid identification of myocardial infarction risk associated with diabetes medications using electronic medical records. Diabetes Care 2009; 33: 526-531.
26. Evans JM, Ogston SA, Emslie-Smith A, Morris AD. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 2006; 49: 930-936.
27. Garratt KN, Brady PA, Hassinger NL, Grill DE, Terzic A, Holmes DR Jr. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol 1999; 33: 119-124.
28. Hsiao FY, Huang WF, Wen YW, Chen PF, Kuo KN, Tsai YW. Thiazolidinediones and cardiovascular events in patients with type 2 diabetes mellitus: a retrospective cohort study of over 473 000 patients using the National Health Insurance database in Taiwan. Drug Saf 2009; 32: 675-690.
29. Johannes CB, Koro CE, Quinn SG, Cutone JA, Seeger JD. The risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy. Pharmacoepidemiol Drug Saf 2007; 16: 504-512.
30. Johnson JA, Majumdar SR, Simpson SH, Toth EL. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care 2002; 25: 2244-2248.
31. Johnson JA, Simpson SH, Toth EL, Majumdar SR. Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with Type 2 diabetes. Diabet Med 2005; 22: 497-502.
32. Jorgensen CH, Gislason GH, Andersson C, Ahlehoff O, Charlot M, Schramm TK, et al. Effects of oral glucose-lowering drugs on long term outcomes in patients with diabetes mellitus following myocardial infarction not treated with emergent percutaneous coronary intervention-a retrospective nationwide cohort study. Cardiovasc Diabetol 2010; 9: 54.
33. McAfee AT, Koro C, Landon J, Ziyadeh N, Walker AM. Coronary heart disease outcomes in patients receiving antidiabetic agents. Pharmacoepidemiol Drug Saf 2007; 16: 711-725.
34. Mellbin LG, Malmberg K, Norhammar A, Wedel H, Ryden L. The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMII 2 trial. Eur Heart J 2008; 29: 166-176.
35. Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Jain A, et al. The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis. Acta Diabetol 2009; 46: 145-154.
36. Schramm TK, Gislason GH, Vaag A, Rasmussen JN, Folke F, Hansen ML, et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J 2011; 32: 1900-1908.
37. Sillars B, Davis WA, Hirsch IB, Davis TM. Sulphonylurea-metformin combination therapy, cardiovascular disease and all-cause mortality: The Fremantle Diabetes Study. Diabetes Obes Metab 2010; 12: 757-765.
38. Sullivan D, Forder P, Simes J, Whiting M, Kritharides L, Merrifield A et al. Associations between the use of metformin, sulphonylureas, or diet alone and cardiovascular outcomes in 6005 people with type 2 diabetes in the FIELD Study. Diabetes Res Clin Pract 2011; 94: 284-290.
39. Tzoulaki I, Molokhia M, Curcin V, Little MP, Millett CJ, Ng A, et al. Risk of cardiovascular disease and all-cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. Br Med J 2009; 339: b4731.
40. Walker AM, Koro CE, Landon J. Coronary heart disease outcomes in patients receiving antidiabetic agents in the pharmetrics database 2000-2007. Pharmacoepidemiol Drug Saf 2008; 17: 760-768.
41. Dormuth CR, Maclure M, Carney G, Schneeweiss S, Bassett K, Wright JM. Rosiglitazone and myocardial infarction in patients previously prescribed metformin. PLoS One 2009; 4: e6080.
42. Horsdal HT, Sondergaard F, Johnsen SP, Rungby J. Antidiabetic treatments and risk of hospitalisation with myocardial infarction: a nationwide case-control study. Pharmacoepidemiol Drug Saf 2011; 20: 331-337.
43. Sadikot SM, Mogensen CE. Risk of coronary artery disease associated with initial sulphonylurea treatment of patients with type 2 diabetes: a matched case-control study. Diabetes Res Clin Pract 2008; 82: 391-395.
44. Sauer WH, Cappola AR, Berlin JA, Kimmel SE. Insulin sensitizing pharmacotherapy for prevention of myocardial infarction in patients with diabetes mellitus. Am J Cardiol 2006; 97: 651-654.
45. Meinert CL, Knatterud GL, Prout TE, Klimt CR. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. Ii. Mortality results. Diabetes 1970; 19: S789-830.
46. UKPDS Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
47. Chang JH, Tseng CF, Wang JY. Hypoglycemia-induced myocardial infarction: an unusual adverse effect of sulfonylureas. Int J Cardiol 2007; 115: 414-416.
48. Pladziewicz DS, Nesto RW. Hypoglycemia-induced silent myocardial ischemia. Am J Cardiol 1989; 63: 1531-1532.
49. Saunders FM, Llewellyn T. Silent myocardial infarction during hypoglycaemic coma. J Accid Emerg Med 1996; 13: 357-358.
50. Mahla E, Tiesenhausen K, Rehak P, Fruhwald S, Purstner P, Metzler H. Perioperative myocardial cell injury: the relationship between troponin T and cortisol. J Clin Anesth 2000; 12: 208-212.
51. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-2471.